Taylor Wessing advises EpilepsyGTx on US$33 million Series A financing

Taylor Wessing advised EpilepsyGTx on its US$33 million Series A financing, which included investment from XGEN Venture, the British Business Bank and a global biopharmaceutical company. The transaction will fund EpilepsyGTx, a London-based biotechnology company developing gene therapies for refractory epilepsy, to progress its lead programme EPY201. EPY201 is an AAV9-based gene therapy administered locally via catheter to the epileptogenic focus, intended to offer patients with focal refractory epilepsy the prospect of seizure freedom from a single, minimally invasive intervention without resection or ablation of brain tissue and without chronic use of multiple antiseizure medications. The financing will enable delivery of a first-in-human Phase 1/2a clinical trial, expected to begin in the UK and Europe by the end of 2026, to establish the safety and efficacy of EPY201 in up to 30 adults with focal refractory epilepsy. Nicolas Koebel, Chief Executive Officer of EpilepsyGTx, said that refractory epilepsy is a devastating condition affecting millions worldwide and that EPY201 delivered directly to the seizure focus has the potential to stop seizures with a single, minimally invasive administration, changing the way refractory epilepsy has been treated for decades. Commenting on the transaction, Corporate Partner Ross McNaughton said that gene therapy represents a transformative approach to treating previously intractable neurological conditions such as focal refractory epilepsy and that Taylor Wessing was pleased to have acted for EpilepsyGTx in this significant fundraising round. Taylor Wessing represented EpilepsyGTx with a team composed by: Ross McNaughton (Partner, Corporate), Bella Thornton-Clark (Senior Associate, Corporate) and Phoebe Sennett (Associate, Corporate).

Taylor Wessing advises EpilepsyGTx on US$33 million Series A financing

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads